Related references
Note: Only part of the references are listed.Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model
Robin Q. H. Kloos et al.
HAEMATOLOGICA (2021)
Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia
Claudia Lanvers-Kaminsky et al.
LEUKEMIA & LYMPHOMA (2020)
A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage
Bernard L. Marini et al.
LEUKEMIA & LYMPHOMA (2019)
Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions
Stacy L. Cooper et al.
PEDIATRIC BLOOD & CANCER (2019)
PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability
Anupam Verma et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2019)
Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia
Michael J. Burke et al.
LEUKEMIA & LYMPHOMA (2017)
Catalyzing improvements in ALL therapy with asparaginase
Bernard L. Marini et al.
BLOOD REVIEWS (2017)
Analysis of Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General Population
Qi Yang et al.
ANALYTICAL CHEMISTRY (2016)
Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals
Bing-Mae Chen et al.
ANALYTICAL CHEMISTRY (2016)
Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice
Sabine M. Poppenborg et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation
Inge M. van der Sluis et al.
HAEMATOLOGICA (2016)
Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer
Nancy J. Ganson et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?
Christian Lubich et al.
PHARMACEUTICAL RESEARCH (2016)
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation
Inge M. van der Sluis et al.
HAEMATOLOGICA (2016)
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial
Andrew E. Place et al.
LANCET ONCOLOGY (2015)
Asparaginase pharmacokinetics and implications of therapeutic drug monitoring
Barbara Asselin et al.
LEUKEMIA & LYMPHOMA (2015)
Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein
Yu Mima et al.
MOLECULAR PHARMACEUTICS (2015)
Acute Lymphoblastic Leukemia in Children
Stephen P. Hunger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pharmacokinetic and Clinical Considerations for Monitoring Asparaginase Activity Levels During Pegaspargase Therapy
Lydia Benitez et al.
PEDIATRIC BLOOD & CANCER (2015)
Anti-PEG immunity: emergence, characteristics, and unaddressed questions
Qi Yang et al.
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2015)
Anti-PEG antibody bioanalysis: a clinical case study with PEG-IFN--1a and PEG-IFN-2a in naive patients
Heather Myler et al.
BIOANALYSIS (2015)
PEG-Asparaginase Allergy in Children With Acute Lymphoblastic Leukemia in the NOPHO ALL2008 Protocol
Louise Tram Henriksen et al.
PEDIATRIC BLOOD & CANCER (2015)
New FDA Draft Guidance on Immunogenicity
Ashwin Parenky et al.
AAPS JOURNAL (2014)
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia
Wing H. Tong et al.
BLOOD (2014)
The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells
Wai Kin Chan et al.
BLOOD (2014)
Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia
Louise T. Henriksen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol Escherichia coli L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4
Anne L. Angiolillo et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients
Michael S. Hershfield et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials
Andrea Willer et al.
BLOOD (2011)
L-Asparaginase Treatment in Acute Lymphoblastic Leukemia
Rob Pieters et al.
CANCER (2011)
A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers
Yijuan Liu et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2011)
Peg-asparaginase for acute lymphoblastic leukemia
Michael Rytting
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
HIGH PREVALENCE OF PRE-EXISTING ANTIBODIES AGAINST POLYETHYLENE GLYCOL (PEG) IN HEPATITIS C (HCV) PATIENTS WHICH IS NOT ASSOCIATED WITH IMPAIRED RESPONSE TO PEG-INTERFERON
H. Tillmann et al.
JOURNAL OF HEPATOLOGY (2010)
Pegasparaginase: where do we stand?
Amer Zeidan et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
PEG-uricase in the management Of treatment-resistant gout and hyperuricemia
Merry R. Sherman et al.
ADVANCED DRUG DELIVERY REVIEWS (2008)
The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats
Tatsuhiro Ishida et al.
JOURNAL OF CONTROLLED RELEASE (2008)
PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner
Tatsuhiro Ishida et al.
JOURNAL OF CONTROLLED RELEASE (2007)
Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients
Jonathan K. Armstrong et al.
CANCER (2007)
FDA drug approval summary: Pegaspargase (Oncaspar (R)) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)
Patricia Anne Dinndorf et al.
ONCOLOGIST (2007)
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase
NJ Ganson et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products
C Fruijtier-Pölloth
TOXICOLOGY (2005)
Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations - The past, the present and recommendations for the future
VI Avramis et al.
CLINICAL PHARMACOKINETICS (2005)
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates
P Caliceti et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
Pegaspargase: a review of clinical studies
ML Graham
ADVANCED DRUG DELIVERY REVIEWS (2003)
Effect of pegylation on pharmaceuticals
JM Harris et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Share Paper
